Free Trial
NASDAQ:MOTS

Motus GI 3/18/2024 Earnings Report

Motus GI EPS Results

Actual EPS
-$4.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Motus GI Revenue Results

Actual Revenue
$0.06 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Motus GI Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Motus GI Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Motus GI Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Motus GI? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Motus GI and other key companies, straight to your email.

About Motus GI

Motus GI (NASDAQ:MOTS) operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

View Motus GI Profile

More Earnings Resources from MarketBeat